Colorectal cancer has the highest occurrence of p53 mutations, with 53% in all colon cancer samples and approximately 70% in recurrent samples (Gao et al., 2022), resulting in the loss of tumor-suppressing function, which endows tumor cells with an advantage by preventing intrinsic tumor suppressive responses such as senescence and apoptosis in response to chemotherapy (Hu et al., 2021). Here, TP53 is linked to neoplasm.